Everest Medicines
Everest Medicines (HKEX: 1952), a Shanghai-based biopharmaceutical company, has executed a landmark out-licensing deal for its civorebrutinib program to Travere Therapeutics, marking a strategic pivot from importing Western assets to originating molecules with global value. The agreement, announced in June 2026, grants Travere exclusive rights...
Bullish Signals
- Everest secured $1.14B civorebrutinib out-licensing deal.
- NEFECON generated RMB 303M revenue H1 2025.
- H1 2025 revenues rose 48% YoY to RMB 446.1M.
- Everest raised HK$1.55B via August 2025 share placement.
- VELSIPITY received NMPA approval for ulcerative colitis Feb 2026.
Bearish Signals
- Civorebrutinib efficacy failure risks $1.03B milestone payments.
- NEFECON revenue depends on H1 2025 NRDL momentum.
- mRNA programs EVM16/18 remain unproven in early stages.